US 12,263,142 B2
Method of treating cancer using selective estrogen receptor modulators
Suzanne E. Wardell, Durham, NC (US); Erik R. Nelson, Champaign, IL (US); and Donald P. McDonnell, Chapel Hill, NC (US)
Assigned to Duke University, Durham, NC (US)
Filed by Duke University, Durham, NC (US)
Filed on Aug. 29, 2023, as Appl. No. 18/457,567.
Application 18/457,567 is a continuation of application No. 17/558,731, filed on Dec. 22, 2021, granted, now 11,779,552.
Application 17/558,731 is a continuation of application No. 16/549,828, filed on Aug. 23, 2019, abandoned.
Application 16/549,828 is a continuation of application No. 15/129,197, granted, now 10,420,734, issued on Sep. 24, 2019, previously published as PCT/US2015/023216, filed on Mar. 28, 2015.
Application 15/129,197 is a continuation in part of application No. 14/512,061, filed on Oct. 10, 2014, granted, now 9,421,264, issued on Aug. 23, 2016.
Claims priority of provisional application 62/129,379, filed on Mar. 6, 2015.
Claims priority of provisional application 61/971,627, filed on Mar. 28, 2014.
Prior Publication US 2023/0398085 A1, Dec. 14, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/137 (2006.01); A61K 9/00 (2006.01); A61K 31/136 (2006.01); A61K 31/138 (2006.01); A61K 31/40 (2006.01); A61K 31/4196 (2006.01); A61K 31/4535 (2006.01); A61K 31/565 (2006.01); A61K 31/5685 (2006.01); A61K 45/06 (2006.01); C07C 217/78 (2006.01); C07C 217/84 (2006.01)
CPC A61K 31/137 (2013.01) [A61K 9/0019 (2013.01); A61K 31/136 (2013.01); A61K 31/138 (2013.01); A61K 31/40 (2013.01); A61K 31/4196 (2013.01); A61K 31/4535 (2013.01); A61K 31/565 (2013.01); A61K 31/5685 (2013.01); A61K 45/06 (2013.01); C07C 217/78 (2013.01); C07C 217/84 (2013.01); A61K 2121/00 (2013.01)] 14 Claims
 
1. A method of treating estrogen receptor positive breast cancer brain metastasis in a subject, the method comprising administering a compound of (R)-6-{2-{ethyl [4-(2-ethylaminoethyl) benzyl] amino}-4-methoxyphenyl}-5,6,7,8-tetrahydronaphthalen-2-ol, wherein the estrogen receptor positive breast cancer brain metastasis is resistant to an aromatase inhibitor.